29 completed, 3 recruiting, 2 unknown, 1 active not recruiting. 38 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 38 | Completed 29, Recruiting 3, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Suspended 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Pulmonary Tuberculosis: new trials by email Literature Review of Pulmonary Tuberculosis trials Research Report on Pulmonary Tuberculosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT Pyrazinamide and Hydroxychloroquine (AI-Optimised), Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) - Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Ministry of Health, Saudi Arabia | 200 | 2026-09-01 | 2026-03-12 |
| Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis | Phase 2 | Suspended | National Institute of Allergy and Infectious Diseases (NIAID) | 341 | 2025-03-11 | 2026-11-02 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| ATORvastatin in Pulmonary TUBerculosis Atorvastatin 20mg, Atorvastatin 40mg, Atorvastatin 60mg - Pulmonary Tuberculosis, Tuberculosis | Phase 2 | Recruiting | Obafemi Awolowo University Teaching Hospital | 440 | 2024-01-03 | 2025-09-25 |
| Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis sorfequiline, Pretomanid, Linezolid - Pulmonary TB, Pulmonary Tuberculosis | Phase 2 | Active not recruiting | Global Alliance for TB Drug Development | 309 | 2023-10-31 | 2026-06-24 |
| Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) - Pulmonary Tuberculosis | Phase 2 | Terminated | Gates Medical Research Institute | 93 | 2023-07-26 | 2026-05-20 |
| PanACEA - STEP2C -01 BTZ-043, Rifampicin, Isoniazid - Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis | Phase 2 | Recruiting | Michael Hoelscher | 390 | 2023-04-14 | 2025-10-07 |
| Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) Isoniazid, Rifampicin, Ethambutol - Tuberculosis, Pulmonary Tuberculosis | Phase 2 | Completed | University of Massachusetts, Worcester | 112 | 2022-03-04 | 2026-08-06 |
| PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) Delpazolid, Bedaquiline, Delamanid, Moxifloxacin - Infections and Infestations, Pulmonary Tuberculosis | Phase 2 | Completed | LigaChem Biosciences, Inc. | 76 | 2021-10-28 | 2025-09-16 |
| PanACEA Sutezolid Dose-finding and Combination Evaluation Sutezolid, Bedaquiline, Delamanid, Moxifloxacin, Midazolam oral solution - Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis | Phase 2 | Completed | Michael Hoelscher | 75 | 2021-05-06 | 2023-05-01 |
| Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081 WX-081, Bedaquiline, Standard treatment - Pulmonary Tuberculosis | Phase 2 | Completed | Shanghai Jiatan Pharmatech Co., Ltd | 99 | 2020-10-16 | 2023-09-11 |
| Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct Rosuvastatin 10mg, Rifampicin, Isoniazid - Pulmonary Tuberculosis | Phase 2 | Unknown | National University Hospital, Singapore | 154 | 2020-08-12 | 2020-08-07 |
| StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis Pravastatin, Rifafour, Vitamin B6 - Tuberculosis, Pulmonary Tuberculosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 16 | 2020-02-21 | 2023-09-18 |
| Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis TBA-7371, HRZE - Pulmonary Tuberculosis | Phase 2 | Completed | Gates Medical Research Institute | 93 | 2020-01-16 | 2024-04-11 |
| PRACTECAL-PKPD Sub Study Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Unknown | Medecins Sans Frontieres, Netherlands | 240 | 2019-08-06 | 2021-05-14 |
| Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers Faropenem, Amoxicillin/clavulanic acid, Cefadroxil - Pulmonary Tuberculosis | Phase 2 | Completed | National University Hospital, Singapore | 58 | 2019-02-11 | 2020-03-23 |
| Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis Meropenem 6g IV over 6 hours, Ertapenem 1g IM, Meropenem 3g IV - Pulmonary Tuberculosis | Phase 2 | Completed | TASK Applied Science | 134 | 2017-11-09 | 2023-06-09 |
| Using Biomarkers to Predict TB Treatment Duration Saliva collection, Urine collection, Sputum collection - Pulmonary Tuberculosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 946 | 2017-06-21 | 2024-04-17 |
| A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK LCB01-0371 800mg, QD, LCB01-0371 400mg, BID, LCB01-0371 800mg, BID - Pulmonary Tuberculosis | Phase 2 | Completed | LigaChem Biosciences, Inc. | 79 | 2016-12-10 | 2020-02-06 |
| Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion Placebo, ID93 + GLA-SE - Pulmonary Tuberculosis | Phase 2 | Completed | Access to Advanced Health Institute (AAHI) | 60 | 2015-06-01 | 2019-03-12 |
Showing 20 of 38. Sign in to see all of them.
Tuberculosis, Pulmonary (38) · Tuberculosis (15) · Tuberculosis, Multidrug-Resistant (3) · Extensively Drug-Resistant Tuberculosis (2) · Gram-Positive Bacterial Infections (1) · HIV Infections (1) · Infections (1) · Mycobacterium Infections (1) · Pneumonia (1)
Actinomycetales Infections (38) · Bacterial Infections (38) · Bacterial Infections and Mycoses (38) · Lung Diseases (38) · Respiratory Tract Diseases (38) · Respiratory Tract Infections (38) · Gram-Positive Bacterial Infections (37) · Infections (37) · Mycobacterium Infections (37) · Tuberculosis (23) · Blood-Borne Infections (1) · Communicable Diseases (1) · Genital Diseases (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1)
Pyrazinamide (14) · Rifampin (13) · Isoniazid (12) · pretomanid (12) · Ethambutol (11) · bedaquiline (11) · Linezolid (7) · Moxifloxacin (7) · OPC-67683 (5) · delpazolid (4) · PNU-100480 (3) · Protons (3) · 2-(2-methyl-1,4-dioxa-8-azaspiro(4.5)dec-8-yl)-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one (2) · Amoxicillin-Potassium Clavulanate Combination (2) · Clofazimine (2)
Global Alliance for TB Drug Development (8) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Gates Medical Research Institute (2) · LigaChem Biosciences, Inc. (2) · Michael Hoelscher (2) · National University Hospital, Singapore (2) · TASK Applied Science (2) · Access to Advanced Health Institute (AAHI) (1) · Centers for Disease Control and Prevention (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · Johns Hopkins University (1) · Medecins Sans Frontieres, Netherlands (1) · Ministry of Health, Saudi Arabia (1) · NMP Medical Research Institute (1) · Obafemi Awolowo University Teaching Hospital (1)
South Africa (25) · Uganda (7) · Tanzania (6) · Philippines (5) · Vietnam (3) · Brazil (2) · China (2) · India (2) · Malawi (2) · Singapore (2) · South Korea (2) · United States (2) · Bangladesh (1) · Belarus (1) · Botswana (1)
Andreas Diacon, MD (3) · Rodney Dawson, MD (3) · Andreas Diacon (2) · Clifton E Barry, Ph.D. (2) · Nicholas Paton (2) · Adreas Diacon (1) · Andreas H Diacon, Dr. (1) · Bern Nyang'wa, MB BS, MPH (1) · Bolanle A Omotoso, MD (1) · Christo van Niekerk (1) · Clifton Barry, Ph.D. (1) · Guang Ji (1) · Hardy Kornfeld, MD (1)
PMID 22430968, PMID 22828481, PMID 22850121, PMID 23075177, PMID 23590701, PMID 25489785, PMID 25622149, PMID 25795076, PMID 26394045, PMID 29528048, PMID 29973153, PMID 31988102, PMID 32381098, PMID 33229425, PMID 33306991, PMID 33374006, PMID 33951066, PMID 34252302, PMID 34489274, PMID 34871098, PMID 35366820, PMID 35636648, PMID 36455068, PMID 36966799, PMID 37280643, PMID 38436463, PMID 39016594, PMID 39622823, PMID 39651910, PMID 40195983, PMID 40645196, PMID 40645198, PMID 40817073, PMID 41616265, PMID 41917253, PMID 42270675, PMID 42560062
U01AI134585 (1)